IQVIA Holdings (IQV) is down about 3.28% to $163.16 as the market keeps discounting the company’s 2026 earnings power after management’s full-year 2026 adjusted EPS guidance range of $12.55–$12.85 failed to clear prior consensus expectations, with higher net interest expense flagged as a key drag. That guidance setup has left the stock sensitive to any incremental negative read-through on financing costs, valuation, and growth durability across its contract research and analytics businesses. (tipranks.com)

IQVIA’s decline also fits the broader risk-off tone that has periodically weighed on growth-oriented healthcare services and CROs in 2026, where investors have been quick to sell on any sign that earnings visibility is being capped by costs or client decision delays. With CRO equities already under pressure year-to-date in many portfolios, single-name drops can accelerate even without a fresh company-specific headline. (trefis.com)

Recent analyst discussion has focused on the idea that higher interest expense is a real, mechanical headwind to 2026 EPS for IQVIA, while debates about AI-driven workflow changes and competitive dynamics have introduced a new valuation discount for some investors. Earlier in 2026, TD Cowen commentary explicitly highlighted AI-related risk in conjunction with a more cautious stance on valuation, reinforcing the “multiple compression” narrative that can pressure the shares on down days. (tikr.com)

Traders will likely focus on whether IQVIA reiterates or tightens its 2026 outlook, any evidence that backlog conversion and bookings remain resilient, and whether interest expense assumptions change meaningfully as refinancing and debt costs flow through the P&L. Any new analyst downgrades/target cuts or broader CRO-sector selling could keep near-term volatility elevated around the stock. (tipranks.com)